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Background: Highly pathogenic H5N1 avian influenza viruses pose a debilitating pandemic threat in poultry. Current
influenza vaccines predominantly focus on hemagglutinin (HA) which anti-HA antibodies are often neutralizing, and are
used routinely to assess vaccine immunogenicity. However, Neuraminidase (NA), the other major glycoprotein on the
surface of the influenza virus, has historically served as the target for antiviral drug therapy and is much less studied in
the context of humoral immunity. The aim of this study was to evaluate the protective immunity of NA based on
Lactococcus lactis (L.lactis) expression system against homologous H5N1 virus challenge in a chicken model.
Results: L.lactis/pNZ2103-NA which NA is derived from A/Vietnam/1203/2004 (H5N1) (VN/1203/04) was constructed
based on L.lactis constitutive expression system in this study. Chickens vaccinated orally with 1012 colony-forming unit
(CFU) of L.lactis/pNZ2103-NA could elicit significant NA-specific serum IgG and mucosa IgA antibodies, as well as
neuraminidase inhibition (NI) titer compared with chickens administered orally with saline or L.lactis/pNZ2103 control.
Most importantly, the results revealed that chickens administered orally with L.lactis/pNZ2103-NA were completely
protected from a lethal H5N1 virus challenge.
Conclusions: The data obtained in the present study indicate that recombinant L.lactis/pNZ2103-NA in the absence of
adjuvant can be considered an effective mucosal vaccine against H5N1 infection in chickens via oral administration.
Further, these findings support that recombinant L.lactis/pNZ2103-NA can be used to perform mass vaccination in
poultry during A/H5N1 pandemic.
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Rapid worldwide dissemination of highly pathogenic
avian influenza (HAPI) H5N1 viruses among poultry
and ongoing viral evolution through genetic drift and
reassortment raise concerns of a potential influenza pan-
demic [1]. HAPI H5N1 virus has emerged in Southeast
Asian and resulted in the destruction of millions of birds
[2]. Concerns about the potential for the generation of a
pandemic H5 strain and its concomitant morbidity and* Correspondence: hlei@binghamton.edu
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Vaccination is the most safe and effective way to prevent
and control H5N1 infection in poultry. Currently, two
commercial inactivated H5N1vaccines (Re-1 and Re-5)
have been widely applied in domestic duck in many
Asian countries [3]. However, these approved vaccines
against H5N1 viruses produced in fertilized eggs have ser-
ious limitations, particularly the limited capability of produ-
cing conventional inactivated influenza H5N1 vaccines
could severely hinder the ability to control the pandemic
spread of avian influenza through vaccination [1,4]. In
addition, conventional vaccines utilizing the hemagglutinin
(HA) of H5N1 viruses have been poor immunogenicity and
have safety issues [4]. Although novel approaches, such ass is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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show some promising signs against H5N1 infection in mice
or poultry [5-8], the risk of generating a reassortant prohibit
the use of this vaccine in most instances. Therefore, there is
a clear need for a new vaccine strategy in poultry that pro-
vides increasing immunogenicity and safety.
For mucosal immunization, lactic acid bacterium (LAB)
is more attractive vaccine delivery system than other live
vaccine vehicles, such as Shigella, Salmonella, and Listeria
[9-11]. Lactococcus lactis (L.lactis), a typical model of lac-
tic acid bacteria, is an ideal vaccine delivery vector and has
been engineered to express many viral antigens [12,13]. It
was shown previously that L.lactis, expressing hemagluti-
nin (HA) from A/chicken/Henan/12/2004(H5N1) and
then coated by enteric capsule, is a safe and effective vac-
cine against avian influenza H5N1 virus infection in mice
[14]. Similarly, it was described that HA1 from A/chicken/
Henan/12/2004(H5N1) virus was displayed on the sur-
face of L.lactis, and showed it to be protective against
homologous H5N1 virus by oral co-administration with
CTB in mice [15]. Recently, it also shown that intranasal
immunization of L.lactis-HA combined with mucosal
adjuvant LTB could provide protection against homolo-
gous H5N1 in chickens [16]. However, most of these
vaccines focus on raising a humoral response against
hemagglutintin (HA) of H5N1 viruses. Neuraminidase
(NA) is another major glycoprotein on the surface of
the virus and has historically served as the target for
antiviral drug therapy and is much less studied in the
context of humoral immunity [17]. It remains largely
unknown regarding the immunogenicity of recombinant
L.lactis expressing neuraminidase (NA) in poultry via
oral administration.
In the present study, we develop a constitutive expres-
sion system by constructing recombinant L.lactis ex-
pressing NA gene from A/Vietnam/1203/2004 (H5N1)
(VN/1203/04) and then evaluating its immunogenicity
via oral administration without the use of adjuvant in a
chicken model. This study reported here suggests that
this system can be used as a platform technology to de-
velop a mucosal NA vaccine for preventing and control-
ling H5N1 infection in poultry.
Methods
Construction of plasmid expressing NA and expression
on L.lactis
The NA gene (1459 bp) of A/Vietnam/1203/2004 (H5N1)
was PCR-amplified from pCDNA3.1-HA (kindly provided
by St. Jude Children’s Research Hospital, Memphis, TN,
USA) using the following primers: NA-F: CTAGCTAGC
GGTACCGCCGCCACCATGAA (Nhe I); NA-R: CCGA
AGCTTACAGGAAGTATTCAATC (Hind III) and cloned
into L.lactis based constitutive expression plasmid
pNZ2103 (purchased from MoBiTec, Goettingen,Germany), the resulting plasmid was transformed into
competent L.lactis NZ3000, the positive clone was
named as L.lactis/pNZ2103-NA.
Western blot analysis was described previously [14]
and L.lactis/pNZ2103 was used as a negative control.
Animal experiments and sample collection
For oral administration of chickens, 7-day-old specific-
pathogen-free (SPF) single comb white leghorn chickens
from an in-house flock (Institute of Jiangxi Agriculture,
China) were used in this study. The concentration of re-
combinant L.lactis/pNZ2103-NA was adjusted to 1012
colony forming unit (CFU)/ml with sterile saline.
Three groups of 16 chickens each were immunized with
oral administration of 1 ml of sterile saline, 1012 CFU of L.
lactis/pNZ2103 or 1012 CFU of L.lactis/pNZ2103-NA, re-
spectively. Prime immunization was performed at day 0, 1,
2, 3 and boosted at day 17, 18, 19, 20.
At day 15 and day 34 after the first immunization,
blood samples were collected from the retro-orbital
plexus. Sera were separated by centrifugation of blood at
2,000 × g for 10 min and stored at -20°C until use. Intes-
tine and upper respiratory were isolated from the vacci-
nated chickens and washed with 500 μL sterile saline,
respectively.
At two weeks after the last immunization, chickens
were lightly anesthetized with CO2 and inoculated intra-
nasally with 25 μl of 104 EID50 of VN/1203/04 virus
through the choanal slit to determine protection efficacy.
Chickens were observed for illness, weight loss, and
death for 14 days after H5N1 virus infection. H5N1 virus
challenge experiments must be strictly performed under
the enhanced bio-safety level-3 laboratory (BSL-3).
The chickens were managed with pelleted feed and ster-
ile water, maintained in a SPF environment and all efforts
were made to minimize suffering following approval from
the Institute Animal Care and Use Committee of the
Nanchang University (Approval No. 726-14).Enzyme-linked immunosorbent assay (ELISA)
Immune sera from the vaccinated chickens were collected
by bleeding from the wing vein and treated with receptor-
destroying enzyme from Vibrio cholerae (Denka-Seiken,
San Francisco, CA) before being tested for the presence of
H5-specific antibodies as described previously [16].
NA-specific immunoglobulin G (IgG) and secretory
immunoglobulin A (IgA) antibodies were detected by
enzyme-linked immunosorbent assay (ELISA) using re-
combinant NA protein as a coating antigen as described
previously [14]. ELISA end point titers were expressed
as the highest dilution that yielded an optical density
greater than twice the mean plus one standard deviation
of that of similarly diluted negative control samples.
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The anti-NA immune response was evaluated by
Bioluminescence-based neuraminidase inhibition kit. To
perform this, 50 μl of chickens sera from each group
was taken at 1/2 dilutions which were half diluted fur-
ther till 1/1024 in a 96-well micro-titer plate. 50 μl of
purified rNA (0.25 mg/ml) was added to each well and
incubated at 37°C for 2 h. The neuraminidase inhibition
titer was represented as the highest dilution until there
was no neuraminidase activity observed.
Data analysis
Data are presented as the means ± standard deviations
(S.D.) and are representative of at least three independ-
ent experiments. All analysis for statistically significant
differences was performed by the Student t test and one-
way ANOVA. A p value less than 0.05 was considered to
be significant.
Results
Expression of NA protein on L.lactis
In this study, we generated a constitutive plasmid
pNZ2103-NA containing NA gene from A/Vietnam/1203/
2004 (H5N1) (Figure 1A). Expression of NA protein on L.
lactis NZ3000 was confirmed by western blotting using
anti-HA monoclonal antibody (Figure 1B). As we ex-
pected, there is no band shown in the L.lactis/pNZ2103
cells, while a specific band was observed at expected
size for NA protein (approximately 54 kDa) (Figure 1B,
Lane 3) in the L.lactis/pNZ2103-NA cells.
Immune responses elicited d by oral administration of
L.lactis/pNZ2103-NA
At day 15 and day 34 after the prime immunization, sera
samples were obtained from all chickens to screen for
antibody responses as a marker of immunogenicity.
There was no significant serum IgG detected between L.
lactis/pNZ2103-NA and saline or L.lactis/pNZ2103
group at day 15 after the prime immunization. However,Figure 1 Construction of pNZ2103-NA and expression of NA protein on
(B) Western blot analysis of recombinant L.lactis/pNZ2103-NA expression. Lan
Protein Standard; Lane 3: L.lactis/pNZ2103-NA. A specific protein band of arou
monoclonal antibody.at day 34 after the prime immunization, chickens admin-
istered orally with L.lactis/pNZ2103-NA could elicit a
higher significant NA-specific IgG titer than other
groups (saline or L.lactis/pNZ2103) (Figure 2A).
To assess the mucosal immune responses, the secretory
mucosal IgA levels were determined by ELISA. Intestinal
and upper respiratory washes were also collected at day 15
and day 34 after the prime immunization. As shown in
Figure 2B and C, L.lactis/pNZ2103-NA induced signifi-
cantly increased levels of NA-specific mucosal IgA com-
pared to saline or L.lactis/pNZ2103 group at day 34 after
the prime immunization in the intestinal and upper re-
spiratory washes. These results are consistent with the de-
tection of serum IgG antibody.
These data demonstrate that chickens vaccinated orally
with L.lactis/pNZ2103-NA after prime-boost immunization
can result in significant IgG and IgA levels which may con-
tribute to protection against virus infection.Neuraminidase inhibition (NI) titers induced by L.lactis/
pNZ2103-NA
Similarly, oral vaccination with L.lactis/pNZ2103-NA in-
duced a higher NI titer compared to other groups (saline
or L.lactis/pNZ2103) (Figure 2D). These results support
that recombinant L.lactis/pNZ2103-NA is immunogenic
without the use of adjuvant in a chicken model.Protection efficacy against H5N1 challenge
At two weeks after the last immunization, all chickens
were challenged by intranasal inoculation with 25 μl of
104 EID50 of VN/1203/04 (H5N1). All chickens immu-
nized orally with saline or L.lactis/pNZ2103 experienced
substantial weight loss beginning at day 2 post challenge
and death by 6 to 8 days post infection. In contrast,
chickens immunized orally with L.lactis/pNZ2103-NA
showed only mild and transient loss of body weight and
survived the lethal challenge (Figure 3).L.lactis. (A) A schematic diagram of constitutive plasmid pNZ2103-NA.
e 1: negative control L.lactis/pNZ2103; Lane 2: MagicMark™ XP Western
nd 54 kDa corresponding to NA was detected using anti-NA
Figure 2 Oral administration of recombinant L.lactis/pNZ2103-NA induces NA-specific immune responses in chickens. Chickens were
immunized orally with saline, L.lactis/pNZ2103 or L.lactis/pNZ2103-NA at day 0, 1, 2, 3 and day 17, 18, 19, 20. Sera (n = 16/group), intestine (n = 3/group)
and upper respiratory (n = 3/group) washes were collected at day 15 and day 34 after the prime immunization. (A) NA-specific IgG antibody was
measured by ELISA in the sera. (B) NA-specific IgA antibody was assessed in the intestinal washes. (C) NA-specific IgA antibody was assessed in the
upper respiratory washes. (D) NI titers were determined using rNA protein. Data are presented as the means ± standard deviations (S.D.). The asterisk
indicates a significant difference between L.lactis/pNZ2103-NA and other groups (saline or L.lactis/pNZ2103) (* p < 0.05).
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Vaccination is an integral component of strategies aim-
ing to prevent and control pandemic influenza in
poultry. Unfortunately, current commercial inactivated
influenza H5N1 vaccines for poultry are generated from
the whole viruses that have serious safety issues and
poor immunogenic [8,18]. Therefore, it is crucial to de-
velop a safe and effective influenza H5N1 vaccine that
can be applied broadly and rapidly in poultry duringH5N1 pandemic. Our previous study has shown that in-
tranasal immunization of L.lactis-HA combined with
LTB can provide protective immunity in chicken [16].
However, most of influenza H5N1 vaccines focus on
HA, it remains unclear that whether NA express on L.
lactis has immunogenicity and poses potential for H5N1
vaccine development in poultry via oral administration.
Further, it is well recognized in the NA field that a vac-
cine that purely raises antibodies to neuraminidase is
Figure 3 Protection efficacy of L.lactis/pNZ2103-NA against H5N1 virus challenge. (A) Weight changes as a percentage. (B) Survival rate.
(n = 10 per group).
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includes some combination of the NA and HA antigen
[19]. Here, we hypothesize that recombinant L.lactis ex-
pressing NA can confer protective immunity against
H5N1 challenge. To address this hypothesis, oral admin-
istration of L.lactis/pNZ2103-NA in the absence of adju-
vant could induce protective immunity against H5N1
infection in a chicken model. This provides an evidence
that L.lactis/pNZ2103-NA can serve as an effective mu-
cosal vaccine to prevent and control H5N1 infection in
poultry without the use of adjuvant.
The mucosal immune system is the first immunological
barrier against the pathogens that invade the body via the
mucosal surface. Thus, the induction of mucosal immun-
ity via mucosal administration (oral or intranasal) is neces-
sary to ensure protection against multiple subtypes of
influenza A virus. Secretion of IgA is a representative anti-
body of mucosal immune response, and confers efficient
protection against acquired mucosal infection [20]. It is an
effective way to construct the incorporation of viral anti-
gen to recombinant L.lactis that is considered essential to
boost the interaction of the vaccine with the mucosal im-
mune system [21]. This study revealed that chickens vacci-
nated orally with optional dosage as 1012 CFU of L.lactis/
pNZ2103-NA was able to induce a significantly higher level
mucosal IgA antibody in intestinal and upper respiratory
washes (Figure 2B and C). Similarly, chickens administered
orally with L.lactis/pNZ2103-NA also elicited a higher
HA-specific IgG titer and NI titer which played an import-
ant role in providing protection against H5N1 lethal infec-
tion (Figure 2A and D). Collectively, these results support
that L.lactis/pNZ2103-NA has a strong immunogenicity
via oral immunization route without the use of adjuvant.
In this regard, L.lactis/pNZ2103-NA can be considered an
effective influenza H5N1 vaccine candidate for poultry.The final protective immunity is most important for vac-
cine development [22]. Monitoring after post infection of
H5N1 virus indicated that there was no significant decrease
in the body weight of chickens vaccinated orally with L.lac-
tis/pNZ2103-NA. In addition, the survival rate revealed that
L.lactis/pNZ2103-NA could provide complete protection
efficacy against highly pathogenic avian influenza H5N1
virus (Figure 3B). These findings suggest that L.lactis/
pNZ2103-NA can be considered an effective influenza
H5N1 vaccine candidate for mass vaccination in poultry. In
addition, influenza vaccines based on L.lactis expression
system have no safety issues, which make this technology
has the potential of becoming one of the most promising
platforms for avian influenza H5N1 vaccine development
in poultry via oral vaccination. Our long-term goal is to
translate these animal studies to preclinical studies, and de-
termine the immunogenicity of recombinant L.lactis based
vaccines in human, and to augment this technology to de-
velop influnenza universal vaccines against different influ-
enza virus subtypes.Conclusion
In conclusion, our findings strongly support oral adminis-
tration of chickens with L.lactis/pNZ2103-NA in the ab-
sence of adjuvant can induce significant humoral and
mucosal immune responses, as well as NI titers in chickens.
Given the induction of protective immunity in the vacci-
nated chickens, widespread immunization of L.lactis/
pNZ2103-NA in susceptible poultry would likely provide a
significant barrier to the spread of H5N1 virus and also be
economically advantageous. Thus, L.lactis/pNZ2103-NA
may be a promising avian influenza H5N1 vaccine candi-
date for poultry in the event of the pandemic spread of
H5N1 virus.
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